Istvan Petak: Precision oncology and AI tools will maximize cancer treatment’s benefits and improve the cost-efficacy ratio

Istvan Petak shared on LinkedIn:

“Hello, Amazing Silicon Valley and Amazing Plug and Play Tech Center. I was thrilled to learn that Genomate Health has been voted into the top 4% of startups by Plug and Play’s corporate partner insurance companies. Insurance companies play a pivotal role in the healthcare ecosystem and are essential partners in our battle against cancer. With their help, we can make precision oncology affordable to those whose lives depend on accessing their right targeted therapy.

Patients want and deserve personalized care. It is heartbreaking and unacceptable when patients cannot afford their right molecularly targeted therapy. Precision oncology supported by algorithmic computational and AI tools will maximize cancer treatment’s benefits and improve the cost-efficacy ratio.

In addition, computational analysis of the real-world frequency of various molecular profiles enables us to forecast the future cost of precision therapy in multiple indications. Thank you, Plug and Play, for building this fantastic worldwide innovation community. Thank you, Plug and Play Team, for supporting me during the event. Together, we can win against cancer.”

Source: Istvan Petak/LinkedIn

Dr. Istvan Petak specialises in precision oncology and molecular pharmacology of targeted therapies. He is the founder and CEO of Genomate Health, Inc. Cambridge, MA, founder and board director of Oncompass Medicine, Budapest, HU, and adjunct professor at the Department of Pharmaceutical Sciences at the University of Illinois at Chicago (UIC).